10-Q: RetinalGenix Technologies Reports Q1 2025 Results: No Revenue, Continued Losses, and Going Concern Uncertainty

RetinalGenix Technologies reports no revenue and a net loss of $587,259 for Q1 2025, with substantial doubt about its ability to continue as a going concern.

Summary

• RetinalGenix Technologies Inc. reported its financial results for the quarter ended March 31, 2025.
• The company has been focused on developing technologies to screen, monitor, diagnose, and treat ophthalmic disorders.
• RetinalGenix has not generated any revenue since its inception.
• For Q1 2025, the company reported a net loss of $587,259, compared to a net loss of $2,145,876 for the same period in 2024.
• Research and development expenses decreased significantly to $13,214 from $83,097 year-over-year.
• Stock-based compensation expenses also decreased substantially to $231,933 from $1,732,834 year-over-year.
• General and administrative expenses increased slightly to $341,203 from $328,985 year-over-year.
• As of March 31, 2025, the company had minimal cash of $3,711 and total liabilities of $1,679,867.
• The company's accumulated deficit stood at approximately $16,017,000 as of March 31, 2025.
• RetinalGenix states it needs approximately $6,000,000 in additional operating capital to complete product development and build infrastructure.
• The company is exploring options for raising additional capital, including equity and debt offerings, strategic partnerships, and licensing arrangements.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• Management has identified a material weakness in internal control over financial reporting due to a lack of segregation of duties.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the lack of revenue, significant losses, minimal cash, going concern uncertainty, and material weakness in internal control.

Positives

• The net loss decreased significantly from $2,145,876 in Q1 2024 to $587,259 in Q1 2025.
• Research and development expenses decreased by 84% year-over-year.
• Stock-based compensation expenses decreased by 87% year-over-year.

Negatives

• The company has not generated any revenue since its inception.
• The company has minimal cash of $3,711 as of March 31, 2025.
• The company has a significant accumulated deficit of approximately $16,017,000 as of March 31, 2025.
• There is substantial doubt about the company's ability to continue as a going concern.
• A material weakness in internal control over financial reporting was identified due to a lack of segregation of duties.

Risks

• The company's ability to continue as a going concern is highly uncertain due to its limited cash reserves and ongoing losses.
• The company's dependence on related parties for financing poses a risk if such support is reduced or terminated.
• The company's failure to raise additional capital could force it to delay, limit, reduce, or terminate its product development or commercialization efforts.
• The material weakness in internal control over financial reporting could lead to inaccurate financial statements and regulatory scrutiny.
• The company's reliance on Sanovas for allocated costs and expenses could be a risk if Sanovas changes its arrangements.

Future Outlook

The company anticipates needing approximately $6,000,000 in additional operating capital to complete product design and testing, develop software tools, and build infrastructure. The company expects to finance its cash needs through public or private equity offerings, debt financings, strategic partnerships, collaborations, and licensing arrangements.

Management Comments

• Management has concluded that our disclosure controls and procedures were ineffective as of March 31, 2025 due to a material weakness in our internal controls.
• Management is actively engaged in the planning for, and implementation of, remediation efforts to address our material weakness and improve our internal control over financial reporting and disclosure controls and procedures.

Industry Context

As a research and development company in the ophthalmic sector, RetinalGenix faces competition from established medical device companies and other emerging players. The company's success depends on its ability to develop and commercialize innovative technologies for diagnosing and treating eye disorders.

Comparison to Industry Standards

• It is difficult to compare RetinalGenix directly to industry standards due to its early stage of development and lack of revenue.
• Comparable companies in the medical device sector often have significant R&D expenses and may rely on venture capital or strategic partnerships for funding.
• The company's ability to secure additional financing and achieve regulatory approval for its products will be critical for its long-term success.

Related Party Transactions

• Sanovas has paid a significant portion of the Company's operating expenses through March 2025, and was owed approximately $177,000 as of March 31, 2025 by the Company.
• The Company issued 296,000 shares of its common stock to offset amounts due to Sanovas for payment of expenses on behalf of the Company of $666,000 during the year ended December 31, 2024.
• From time to time, an officer of the Company, a shareholder of the Company and other related parties advanced funds or paid expenses on behalf of the Company.
• At March 31, 2025 and December 31, 2024, the Company had received an aggregate of $506,748 and $467,793 pursuant to such advances, respectively.

Stakeholder Impact

• Shareholders face significant risk of losing their investment due to the company's financial difficulties and going concern uncertainty.
• Employees may be affected by potential reductions in force or termination of operations if the company cannot secure additional funding.
• Customers may be impacted by delays or termination of product development if the company cannot continue its operations.
• Suppliers and creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company needs to secure additional financing to continue its operations and product development.
• The company needs to address the material weakness in internal control over financial reporting.
• The company needs to complete product design and testing for RetinalGenixTM and RetinalCamTM and submit RetinalGenixTM for FDA clearance.
• The company needs to complete the development and expansion of the software tools around the recently acquired DNA/GPS genetic mapping technology.

Key Dates

Keywords

RetinalGenix, Financial Results, Going Concern, Ophthalmic, Net Loss, R&D, Stock-based Compensation, Liquidity, Capital Resources, Internal Control, Material Weakness